# Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer

> **NCT04674306** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **George T. Budd** · enrollment: 35 (actual)

## Conditions studied

- Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer
- TNBC - Triple-Negative Breast Cancer
- Residual Disease

## Interventions

- **BIOLOGICAL:** α-lactalbumin vaccine
- **BIOLOGICAL:** Zymosan

## Key facts

- **NCT ID:** NCT04674306
- **Lead sponsor:** George T. Budd
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-01
- **Primary completion:** 2025-11
- **Final completion:** 2026-05
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-05-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04674306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04674306, "Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04674306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*